Home > Publications Database > Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. > print

001     138738
005     20240321220506.0
024 7 _ |a 10.1016/j.neuron.2016.05.018
|2 doi
024 7 _ |a pmid:27292537
|2 pmid
024 7 _ |a 0896-6273
|2 ISSN
024 7 _ |a 1097-4199
|2 ISSN
024 7 _ |a altmetric:8613690
|2 altmetric
037 _ _ |a DZNE-2020-05060
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bacioglu, Mehtap
|0 P:(DE-2719)2810940
|b 0
|e First author
|u dzne
245 _ _ |a Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.
260 _ _ |a New York, NY
|c 2016
|b Elsevier
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2016-07-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710344685_30566
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a A majority of current disease-modifying therapeutic approaches for age-related neurodegenerative diseases target their characteristic proteopathic lesions (α-synuclein, Tau, Aβ). To monitor such treatments, fluid biomarkers reflecting the underlying disease process are crucial. We found robust increases of neurofilament light chain (NfL) in CSF and blood in murine models of α-synucleinopathies, tauopathy, and β-amyloidosis. Blood and CSF NfL levels were strongly correlated, and NfL increases coincided with the onset and progression of the corresponding proteopathic lesions in brain. Experimental induction of α-synuclein lesions increased CSF and blood NfL levels, while blocking Aβ lesions attenuated the NfL increase. Consistently, we also found NfL increases in CSF and blood of human α-synucleinopathies, tauopathies, and Alzheimer's disease. Our results suggest that CSF and particularly blood NfL can serve as a reliable and easily accessible biomarker to monitor disease progression and treatment response in mouse models and potentially in human proteopathic neurodegenerative diseases.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
536 _ _ |a 345 - Population Studies and Genetics (POF3-345)
|0 G:(DE-HGF)POF3-345
|c POF3-345
|f POF III
|x 1
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 2
542 _ _ |i 2016-07-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
542 _ _ |i 2017-07-06
|2 Crossref
|u https://www.elsevier.com/open-access/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Axons: metabolism
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Intermediate Filaments: metabolism
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Mice, Transgenic
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: diagnosis
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: metabolism
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: pathology
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
650 _ 2 |a Neurofilament Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a alpha-Synuclein: metabolism
|2 MeSH
700 1 _ |a Maia, Luis F
|0 P:(DE-2719)9000196
|b 1
|u dzne
700 1 _ |a Preische, Oliver
|0 P:(DE-2719)2811828
|b 2
|u dzne
700 1 _ |a Schelle, Juliane
|0 P:(DE-2719)2811018
|b 3
|u dzne
700 1 _ |a Apel, Anja
|0 P:(DE-2719)2812177
|b 4
|u dzne
700 1 _ |a Kaeser, Stephan A
|0 P:(DE-2719)9000387
|b 5
|u dzne
700 1 _ |a Schweighauser, Manuel
|0 P:(DE-2719)9000294
|b 6
|u dzne
700 1 _ |a Eninger, Timo
|0 P:(DE-2719)2811141
|b 7
|u dzne
700 1 _ |a Lambert, Marius
|0 P:(DE-2719)2810762
|b 8
|u dzne
700 1 _ |a Pilotto, Andrea
|0 P:(DE-2719)9000943
|b 9
|u dzne
700 1 _ |a Shimshek, Derya R
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Neumann, Ulf
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Kahle, Philipp J
|0 P:(DE-2719)2810803
|b 12
|u dzne
700 1 _ |a Staufenbiel, Matthias
|0 P:(DE-2719)9000301
|b 13
|u dzne
700 1 _ |a Neumann, Manuela
|0 P:(DE-2719)2810592
|b 14
|u dzne
700 1 _ |a Maetzler, Walter
|0 P:(DE-2719)2810915
|b 15
|u dzne
700 1 _ |a Kuhle, Jens
|0 P:(DE-HGF)0
|b 16
|e Corresponding author
700 1 _ |a Jucker, Mathias
|0 P:(DE-2719)2000010
|b 17
|e Last author
|u dzne
773 1 8 |a 10.1016/j.neuron.2016.05.018
|b : Elsevier BV, 2016-07-01
|n 1
|p 56-66
|3 journal-article
|2 Crossref
|t Neuron
|v 91
|y 2016
|x 0896-6273
773 _ _ |a 10.1016/j.neuron.2016.05.018
|g Vol. 91, no. 1, p. 56 - 66
|0 PERI:(DE-600)2001944-0
|n 1
|q 91:1<56 - 66
|p 56-66
|t Neuron
|v 91
|y 2016
|x 0896-6273
856 4 _ |u https://pub.dzne.de/record/138738/files/DZNE-2020-05060_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/138738/files/DZNE-2020-05060_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:138738
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810940
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000196
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811828
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811018
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812177
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9000387
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000294
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811141
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2810762
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9000943
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2810803
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)9000301
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2810592
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2810915
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2000010
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-345
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Population Studies and Genetics
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 2
914 1 _ |y 2016
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURON : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NEURON : 2017
920 1 _ |0 I:(DE-2719)1210001
|k AG Jucker
|l Cell Biology of Neurological Diseases
|x 0
920 1 _ |0 I:(DE-2719)1210000-4
|k AG Kahle
|l Functional Neurogenetics
|x 1
920 1 _ |0 I:(DE-2719)5000056
|k Ext UKT-Trend
|l Ext UKT TREND Studie
|x 2
920 1 _ |0 I:(DE-2719)1210003
|k AG Neumann
|l Molecular Neuropathology of Neurodegenerative Diseases
|x 3
920 1 _ |0 I:(DE-2719)5000024
|k AG Maetzler
|l Functional Neurogeriatrics
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1210001
980 _ _ |a I:(DE-2719)1210000-4
980 _ _ |a I:(DE-2719)5000056
980 _ _ |a I:(DE-2719)1210003
980 _ _ |a I:(DE-2719)5000024
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21